(EN) The present invention is directed toward a method of treating or inhibiting abnormal cardiac growth. Specifically, the invention involves inhibition of the 12-lipoxygenase pathway or action of the 12-lipoxygenase products, to reduce or eliminate 12-lipoxygenase pathway mediated cardiac hypertrophic effects at a cellular level. Useful compounds are selected from the group consisting of pioglitazone, panaxynol, phenidone, baicalein, and cinnamyl1-3,4-dihydroxy-a-cyanocinnamate, 13(S)-hydroxyoctadecadienoic acid, 2-phenylmethyl-1-naphthol(DuP654), 2-N-butyl-4-cholo-5-hydroxymethyl1-1-[2'-(1H-tetrazol-5-zl)biphenyl-4-yl)methyl] imidazole (Losartan), pertussis toxin, 12(S)-HETE analogs, peptides and peptide analogs having affinity for the binding site on the 23(S)-HETE receptors and antibodies to the 12(S)-HETE receptor.
(FR) L'invention concerne une méthode de traitement ou d'inhibition d'une croissance cardiaque anormale. Notamment, l'invention concerne l'inhibition du mécanisme d'action de la 12-lipoxygénase ou de l'action de produits à base de 12-lipoxygénase, de manière à réduire ou éliminer les effets d'hypertrophie cardiaque induits par le mécanisme d'action de la 12-lipoxygénase au niveau cellulaire.